Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Z. Estrov · SciRah

Researcher profile · Semantic Scholar

Z. Estrov

Share profile

Z. Estrov — researcher profile on SciRah

h-index: 102
Works: 1,047
Citations: 41K

Most-cited papers

Ten-day Decitabine with Venetoclax in Acute Myeloid Leukemia: A Single-arm Phase 2 Trial
C. Dinardo, A. Maiti, C. Rausch, N. Pemmaraju +35 more
2020The Lancet Haematology247 citations Open access
Semantic Scholar
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
N. Jain, M. Keating, P. Thompson, A. Ferrajoli +29 more
2021JAMA Oncology102 citations Open access
Semantic Scholar
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia
P. Bose, S. Verstovsek, J. Cortes, Susan Tse +20 more
2020Leukemia50 citations Open access
Semantic Scholar
Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs.
L. Masarova, C. Dinardo, P. Bose, N. Pemmaraju +8 more
2021Blood Advances49 citations Open access
Semantic Scholar
Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia.
N. Short, K. Patel, M. Albitar, Miguel J. Franquiz +16 more
2020Blood Advances43 citations Open access
Semantic Scholar
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia
Yasmin M. Abaza, H. Kantarjian, Y. Alwash, G. Borthakur +13 more
2020American journal of hematology/oncology42 citations Open access
Semantic Scholar
Improved Survival of Myelofibrosis Patients in the Last Decade: Single Center Experience
L. Masarova, P. Bose, N. Pemmaraju, N. Daver +6 more
2022Cancer40 citations Open access
Semantic Scholar
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome
M. Swaminathan, H. Kantarjian, M. Levis, V. Guerra +20 more
2021Haematologica40 citations Open access
Semantic Scholar
Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.
N. Pemmaraju, B. Carter, P. Bose, N. Jain +20 more
2021Blood Advances34 citations Open access
Semantic Scholar
Long‐term results of frontline dasatinib in chronic myeloid leukemia
A. Maiti, J. Cortes, K. Patel, L. Masarova +15 more
2020Cancer32 citations Open access
Semantic Scholar
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations
N. Jain, P. Thompson, J. Burger, A. Ferrajoli +24 more
2021Leukemia31 citations
Semantic Scholar
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia
G. Montalban-Bravo, D. Hammond, C. Dinardo, M. Konopleva +16 more
2021Leukemia28 citations
Semantic Scholar
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia
N. Short, G. Borthakur, N. Pemmaraju, C. Dinardo +22 more
2022Leukemia and Lymphoma24 citations
Semantic Scholar
CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia
M. Sivina, L. Xiao, Ekaterina Kim, A. Vaca +9 more
2020Leukemia24 citations
Semantic Scholar
Prognostic Value of Blasts in Peripheral Blood in Myelofibrosis in the Ruxolitinib Era
L. Masarova, P. Bose, N. Pemmaraju, N. Daver +6 more
2020Cancer24 citations Open access
Semantic Scholar
Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia
T. Kadia, F. Ravandi, G. Borthakur, M. Konopleva +17 more
2021American journal of hematology/oncology20 citations Open access
Semantic Scholar
Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis
Ivo Veletic, Sanja Prijic, T. Manshouri, G. Nogueras-González +2 more
2020Haematologica20 citations Open access
Semantic Scholar
Achieving Complete Remission in CLL Patients Treated with Ibrutinib: Clinical Significance and Predictive Factors.
P. Strati, E. Schlette, L. M. Solis Soto, D. Dueñas +11 more
2020Blood19 citations Open access
Semantic Scholar
Lymphocytic variant of hypereosinophilic syndrome: A report of seven cases from a single institution
Z. Hu, Wei Wang, B. Thakral, Zhi-Ning Chen +5 more
2020Cytometry. Part B, Clinical cytometry19 citations Open access
Semantic Scholar
Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic phase of chronic myeloid leukemia
L. Masarova, J. Cortes, K. Patel, S. O'Brien +12 more
2020Cancer18 citations Open access
Semantic Scholar
Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis
N. Pemmaraju, B. Carter, H. Kantarjian, J. Cortes +18 more
2019Blood18 citations
Semantic Scholar
Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study
P. Bose, L. Masarova, N. Pemmaraju, S. Bledsoe +20 more
2024Haematologica17 citations Open access
Semantic Scholar
Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data
N. Jain, Michael J. Keating, P. Thompson, A. Ferrajoli +31 more
2023Blood17 citations Open access
Semantic Scholar
miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.
Enrique Fuentes-Mattei, R. Bayraktar, T. Manshouri, Andréia M. Silva +26 more
2020JCI Insight17 citations Open access
Semantic Scholar
Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results
N. Jain, M. Keating, P. Thompson, A. Ferrajoli +29 more
2020Blood17 citations Open access
Semantic Scholar
GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes
T. Manshouri, Ivo Veletic, Ping Li, C. Yin +3 more
2022Cell Death and Disease16 citations Open access
Semantic Scholar
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
N. Jain, P. Thompson, J. Burger, A. Ferrajoli +21 more
2019Blood15 citations
Semantic Scholar
Activation and expansion of T follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures
A. Vaca, N. Ioannou, M. Sivina, E. Vlachonikola +10 more
2022Leukemia14 citations
Semantic Scholar
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia
G. Montalban-Bravo, R. Kanagal-Shamanna, V. Guerra, J. Ramos-Perez +21 more
2020American journal of hematology/oncology14 citations
Semantic Scholar
Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia
G. Montalban Bravo, R. Kanagal-Shamanna, K. Sasaki, L. Masarova +22 more
2020bioRxiv13 citations Open access
Semantic Scholar
Translocation t(1;19)(q23;p13) in Adult Acute Lymphoblastic Leukemia – A Distinct Subtype with Favorable Prognosis
M. Yilmaz, H. Kantarjian, G. Toruner, C. Yin +16 more
2020Leukemia and Lymphoma13 citations
Semantic Scholar
TP53-altered CLL Treated with Firstline Bruton’s Tyrosine Kinase Inhibitor-based Therapy: A Retrospective Analysis
Hua-Jay J. Cherng, R. Khwaja, R. Kanagal-Shamanna, G. Tang +11 more
2022American journal of hematology/oncology12 citations Open access
Semantic Scholar
Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis
P. Bose, L. Masarova, N. Pemmaraju, S. Bledsoe +22 more
2021Blood12 citations Open access
Semantic Scholar
Clinical Significance of Bone Marrow Blast Percentage in Patients with Myelofibrosis and the Effect of Ruxolitinib Therapy
L. Masarova, P. Bose, N. Pemmaraju, N. Daver +5 more
2021Clinical Lymphoma, Myeloma & Leukemia12 citations Open access
Semantic Scholar
Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukaemia
K. Sasaki, H. Kantarjian, W. Wierda, Farhad Ravandi-Kashani +21 more
2020American journal of hematology/oncology12 citations Open access
Semantic Scholar
Phase II Trial of CPX-351 in Patients with Acute Myeloid Leukemia at High Risk for Induction Mortality
G. Issa, H. Kantarjian, L. Xiao, J. Ning +21 more
2020Leukemia11 citations Open access
Semantic Scholar
The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers
R. Bayraktar, Yi-Tao Tang, M. Dragomir, C. Ivan +46 more
2025Science Advances10 citations Open access
Semantic Scholar
STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells
U. Rozovski, Ivo Veletic, D. Harris, Ping Li +12 more
2022Journal of Immunology10 citations Open access
Semantic Scholar
CLL cell-derived exosomes alter the immune and hematopoietic systems
Ivo Veletic, David M. Harris, U. Rozovski, M. T. Bertilaccio +12 more
2025Leukemia9 citations
Semantic Scholar
STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells
U. Rozovski, D. Harris, Ping Li, Zhi-Ming Liu +11 more
2021OncoTarget8 citations Open access
Semantic Scholar
Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
P. Reville, H. Kantarjian, G. Borthakur, M. Yilmaz +19 more
20208 citations Open access
Semantic Scholar
Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).
T. Kadia, G. Garcia-Manero, M. Yilmaz, C. Dinardo +16 more
20207 citations
Semantic Scholar
Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data
N. Jain, M. Keating, P. Thompson, A. Ferrajoli +30 more
2022Blood6 citations Open access
Semantic Scholar
Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study
M. Sivina, N. Jain, Ekaterina Kim, T. Kadia +11 more
20206 citations
Semantic Scholar
Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study
P. Bose, N. Pemmaraju, L. Masarova, S. Bledsoe +21 more
20206 citations
Semantic Scholar
Phase 2 Study of Lenalidomide Maintenance for Patients with High-Risk Acute Myeloid Leukemia in Remission
I. Abou Dalle, H. Kantarjian, F. Ravandi, N. Daver +17 more
2021Cancer5 citations Open access
Semantic Scholar
Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia
Hua-Jay J. Cherng, N. Jammal, S. Paul, Xue-Mei Wang +9 more
2021British Journal of Haematology5 citations Open access
Semantic Scholar
Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
L. Masarova, S. Verstovsek, P. Bose, N. Pemmaraju +18 more
2019Blood5 citations Open access
Semantic Scholar
RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia
G. Montalban-Bravo, F. Darbaniyan, K. Chien, D. Hammond +13 more
2022Blood4 citations Open access
Semantic Scholar
Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents
S. Venugopal, K. Chien, D. Hammond, R. Kanagal-Shamanna +15 more
2021Blood4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Kadia×33
Invite
T. Kadia — researcher profile on SciRah
H. Kantarjian×31
Invite
H. Kantarjian — researcher profile on SciRah
E. Jabbour×30
Invite
E. Jabbour — researcher profile on SciRah
N. Pemmaraju×29
Invite
N. Pemmaraju — researcher profile on SciRah

×28

Invite

N. Daver — researcher profile on SciRah

Invite

N. Jain — researcher profile on SciRah

G. Borthakur×27

Invite

G. Borthakur — researcher profile on SciRah

G. Garcia-Manero×26

Invite

G. Garcia-Manero — researcher profile on SciRah

Invite

P. Bose — researcher profile on SciRah

S. Verstovsek×24

Invite

S. Verstovsek — researcher profile on SciRah

Invite

C. Dinardo — researcher profile on SciRah

M. Konopleva×21

Invite

M. Konopleva — researcher profile on SciRah